Patent for Klaria’s Sumatriptan Alginate Film to be Granted in Mexico

Klaria has received notification that the patent for its Sumatriptan Alginate Film will be granted in Mexico.  This extends the geographic coverage of Klaria’s patent protection in the important North American market.  The period of patent protected exclusivity in Mexico will last until 2037.

UPPSALA, 11 January, 2021. An important part of Klaria’s intellectual property strategy is to file combination patents.  These patents are specific for the combination of the active substance with the Alginate Film.  The granting of the Sumatriptan Alginate Film combination patent in Mexico is further validation of the success of this strategy.   With the approval in 2021 of the Sumatriptan Alginate Film patent in the United States, the Mexican patent approval extends Klaria’s patent protect in the important North American market.

Jesper Wiklund, CEO of Klaria said “This approval marks a continuation of the track record of success of our combination patent strategy.  Klaria is strengthening the patent estate and extending the breadth and lifetime of the intellectual property protection of our products.  Now, Sumatriptan Alginate Film (KL-00119) will be patent protected by two separate and independent patents in Mexico and the period of patent protected exclusivity will last until 2037.”